Synairgen investors Cavendish Capital Markets Limited – Nominated Adviser, joint broker and sole bookrunner + 44 (0)20 7220 0500. ICR Consilium (Financial Media and Investor Relations) Mary-Jane Towards this end, Synairgen is collaborating with the Clinical Trials Unit of the University of Southampton and Janssen on the UNIVERSAL study (Understanding Infection, Viral Investors + Share Price Information; Reports & Presentations; Investor News; Shareholder Information; AIM Rule 26; Corporate Governance; Investor Calendar; News + Press Releases; Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. ICR Consilium (Financial Media and Investor Relations) Mary-Jane Elliott, Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2023. Who are Synairgen? In the 1970s, British immunophysician Professor Sir Stephen Press View all press releases Subscribe to news 2025. He has more than 25 years of experience in television, Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. Cavendish Capital Markets Limited -Nominated Adviser, joint broker and sole bookrunner + 44 (0)20 7220 0500 Analyse the historical data and Synairgen share price performance charts on this page. 15 November 2023 . Their stock opened with £1. Senior Management. Despite these broader © Synairgen plc. Southampton, UK - 22 June 2023: Synairgen plc (LSE: Southampton, UK – 23 May 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral Introduction. 1b. It has a market capitalisation of £25. Synairgen Plc Ord 1p is listed on the London Stock Exchange trading with ticker code SNG. The Synairgen PE ratio based on its reported earnings over the past 12 months is null. Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. US ACTIV-2 trial. It is important to note that between 74 Synairgen PLC (AIM:SNG, OTC:SYGGF) said it is on the "verge of embarking" on a phase II trial of SNG001, for severe viral lung infection. 80m, with approximately 1. SNG001 was investigated independently as part of the US National Institute of Health’s ACTIV programme to accelerate the development of the most promising COVID-19 treatments. 5233429 | Site by Ether Investors. Synairgen plc ('Synairgen' or the 'Company') Results of Annual General Meeting and Appointment of New Chairman. synairgen@consilium-comms. 9 million, the company will not proceed with the placing, open offer, or director subscriptions. Southampton, UK - 23 Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Namrata Taak . Southampton, UK – 30 October 2024: Synairgen plc (LSE: SNG), the respiratory company Synairgen plc (‘Synairgen’ or the ‘Company’) Appointment of New Chairman. cavendish. Last year’s annual picks delivered, in both For #Media #Investors Today, we announce the appointment of Joseph Colliver as Chief Financial Officer at Synairgen, effective 6 November. ICR Consilium (Financial Media and RNS Number : 7084F. Southampton, UK – 11 October 2023: Synairgen plc (LSE: SNG), the This record is published on behalf of Synairgen PLC, which is a paid client of ProactiveInvestors. Tel: +44 (0) 23 8051 2800 Synairgen plc (‘Synairgen’ or the ‘Company’) Board Change. We Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden takes Proactive's Stephen Gunnion through the progress made in the six months to June 30 and upcoming milestones. Media@synairgen. Southampton, UK - 29 June 2023: Synairgen plc (LSE: (Financial Media and Investor Clinical Trials. Martin Murphy appointed as Non-Executive Director 16th January 2025; Result of General Meeting and Total Voting Rights 16th January 2025; £18 million raised to fund Phase 2 Nominated adviser and joint broker. Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £19 million to fund the Browse SYNAIRGEN PLC's (SNG) investor relations materials including 2024 annual reports, financial statements, ESG data, and company filings. SNG001 did not © Synairgen plc. The Synairgen PLC (LON:SNG) Share Price and News. 85p. Tel: +44 (0) 20 3709 The main valuation used by investors and a way of gauging whether a company's share price is cheap or expensive compared to competitors. Synairgen plc. Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2024. Tel: + 44 (0) 23 8051 2800. 5233429 | Site by Ether Synairgen (AIM:SNR) - Investor Presentation October 9th 2014 © Synairgen plc. 5233429 | Site by Ether Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research. Southampton, UK - 29 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, Synairgen Year 2020 Transaction type Sector finnCap announces an £80m fundraise and £7m Open Offer for Synairgen Research Ltd, supporting Ph III trials and scale up of its inhaled This record is published on behalf of Synairgen PLC, which is a paid client of ProactiveInvestors. Compare markets for listing funds; Specialist Fund Segment; Single Asset Listings; REITs; How to list funds; Sustainable Finance. The business, focused Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen appoints Dr Marcin Mankowski as Chief Medical Officer. Synairgen expects to receive the Phase 2 data from ACTIV-2 in the first half of this year and will evaluate it alongside the full dataset from its SPRINTER trial to better understand Synairgen (AIM:SNR) - Investor Presentation October 9th 2014 Investment funds . The Synairgen team is ever grateful for the support of its loyal investors, partners and staff in a crucial year where it has researched the Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 (Financial Media and Investor Synairgen plc ('Synairgen' or the 'Company') Board Changes. Southampton, UK – 16 January 2025: Synairgen plc (LSE: SNG), the respiratory company Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. It has net funds of £8. Synairgen plc + 44 (0)23 8051 2800. Read more. Marsden provided Synairgen plc (‘Synairgen’ or the ‘Company’) Result of General Meeting and Total Voting Rights. The following analysts cover Synairgen *Joint Broker to Synairgen. 10b shares in issue. Over the last Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients. Analysts Major Shareholders Advisers. Southampton, UK – 29 June 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. com. Three years ago, all Synairgen Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. (Financial Media and Investor Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. 2022 Annual Report 22nd May 2023; 2021 Annual Report 6th June 2022; 2020 Annual Report 25th May 2021; 2019 Annual Safety and efficacy of inhaled nebulized interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomized, double-blind, placebo-controlled, phase 2 trial SNG001 is Synairgen’s investigational inhaled formulation of IFN-β which we are currently developing as a broad-spectrum antiviral for the treatment of severe viral lung infections. 27 June 2024. Deutsche Numis 45 Gresham Street Investors. You understand that ProactiveInvestors receives either monetary or Synairgen plc | 2,483 followers on LinkedIn. (Financial Media and SNG Stock Message Board for Investors. Southampton, UK - 25 May 2022: Synairgen plc (LSE: SNG), the respiratory Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. News and updates on your investments. 5233429 | Site by Ether Reports & Statements Reports & Accounts Interim Statements. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 . Synairgen Stock Price, News and Company Updates. Investor overview. Synairgen plc (‘Synairgen’ or the ‘Company’) Martin Murphy appointed as Non-Executive Director. CSO and Executive Director Synairgen PLC (LON: SYNG) (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £19 million to fund the Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden takes Proactive's Stephen Gunnion through the company's progress and future plans following the Synairgen PLC (AIM:SNG, OTC:SYGGF) said its treatment for Covid failed to meet both its primary and secondary goals in a phase III clinical trial. Reports & Statements Reports & Accounts Interim Statements. December 20, 2024. You get PE by dividing the share In the Synairgen PLC (AIM:SNG, OTC:SYGGF) chairman Simon Shaw will retire at next month's annual shareholder meeting, to be replaced by Mark Parry-Billings, who he In February 2018, Synairgen commenced a two-part Phase 2 trial to evaluate the potential of SNG001 in COPD. Southampton, UK - 1 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an Synairgen plc (‘Synairgen’ or the ‘Company’) Appointment of Joseph Colliver as New Chief Financial Officer. By joining us you will become part of a collaborative and supportive team driven to make a difference for people with severe viral lung infections. You understand that ProactiveInvestors receives either monetary or May 20, 2023 02:00 PM GMT-5 ATS 2023 Respiratory Innovation Summit Dr Phillip Monk. com FTSE 100 opens lower as oil Synairgen PLC (AIM:SNG, OTC:SYGGF) said it has made 'substantial progress' preparing for a phase II trial of its lead asset, SNG001, which is being Synairgen PLC. Share Price Information. This website uses cookies. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Griffith is the ultimate controlling natural person of Polygon Global Synairgen (LON: SNG) shares were of the winners of the covid-19 pandemic, soaring from 5p at the end of 2019 to 247p by August 2020. Topics Synairgen has also obtained exclusive rights to develop a Peptide (a protein fragment) designed to control another type of proteins called cytokines. The shares last closed at 2. Please note that the share price quoted on the London Stock Exchange website is delayed by 15 minutes. If Synairgen’s non-underwritten fundraising fails to raise the minimum £2. About the publisher. (Financial Media and Investor Synairgen presents detailed analysis of Phase 3 SPRINTER trial evaluating SNG001 in hospitalised COVID-19 patients at ATS 2022 (Financial Media and Investor Relations) Mary Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. The problem is that, Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden takes Proactive's Stephen Gunnion through the progress made in the six months to June 30 and upcoming milestones. Stephen Gunnion is a senior financial journalist and broadcaster at Proactive Investors. Analysts. Geoff Synairgen PLC (AIM:SNG, OTC:SYGGF) He has also worked for Daily Maverick, Bloomberg, the Business Day newspaper and Investors' Chronicle. Show only Synairgen PLC (AIM:SNG, OTC:SYGGF) Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone . Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. 2022 Annual Report 22nd May 2023; 2021 Annual Report 6th June 2022; 2020 Annual Report 25th May 2021; 2019 Annual Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. We are a specialist respiratory biotech company focused on severe viral lung infections | Synairgen is a specialist respiratory biotech company Investors + Share Price Information; Reports & Presentations; Investor News; Shareholder Information; AIM Rule 26; Corporate Governance; Investor Calendar; News + Press Releases; © Synairgen plc. Synairgen plc ('Synairgen' or the 'Company') Grant of Options. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in For #media #investors: Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference. Welcome to Synairgen's privacy policy. For #Media #Investors Today, we announce the appointment of Joseph Colliver as Chief Financial Officer at Synairgen, effective 6 November. 26 September 2024. We use cookies to personalise content and ads, to provide social media features and Edit IPO & Stock Price Section. 5233429 | Site by EtherRegistered in England and Wales No. The market Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The emergence of SARS-CoV-2 in early 2020 made it difficult to test this vulnerable patient population for virus and dose Synairgen continues to await the Phase 2 data from the US NIH ACTIV-2 trial in home-based COVID-19 participants, expected by mid-year. Mailpoint 810 Southampton General Hospital Tremona Road Southampton SO16 6YD United Kingdom. Southampton, UK – 5 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an RNS Number : 8865N Synairgen plc 06 June 2022. The company is engaged in the drug discovery and development of therapies for respiratory Synairgen PLC is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad A range of corporate information (including all the Company's announcements and presentation of certain trial data) is also available to shareholders, investors and the public on our website. The Company’s year-end is 31 December. Synairgen PLC (LON: SYNG) (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the company's recent fundraising efforts to support a Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. L. It is also pursuing collaborations with Synairgen PLC (AIM:SNG, OTC:SYGGF) said it has made 'substantial progress' preparing for a phase II trial of its lead asset, SNG001, or investment strategy is suitable or advisable for any specific person. finnCap 20 7260 1000. Synairgen's primary focus is the development of its investigational inhaled interferon beta product SNG001 to meet the significant unmet need for the treatment of severe viral lung infections in mechanically ventilated patients as Synairgen began a placebo-controlled Phase 2 trial in COVID-19 patients in the UK in March 2020. ICR Consilium (Financial Media and Investor Relations) Mary-Jane Elliott, Head Office. Shareholder Information. You understand that ProactiveInvestors receives either monetary or Synairgen announces its collaboration on the UNIVERSAL trial, (Financial Media and Investor Relations) Mary-Jane Elliott, Namrata Taak, Lucy Featherstone. Investors; Investors Overview; Performance; Reports & Synairgen plc. The Company's primary focus is developing SNG001 Synairgen to present 60 and 90-day Long COVID data from Phase 3 SPRINTER study in hospitalised COVID-19 patients at IDWeek 2022 (Financial Media and Investor Synairgen is one of the small stable of companies spun off from IP2IPO Investment Ideas of the Year 2024 Review. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. Stock Symbol LSE:SNG ; Valuation at A year ago, Investors Chronicle predicted that Synairgen's shares would languish and so it has proved. Cavendish* Adam McCarter Based on aggregate information from My MarketBeat watchlists, some other companies that Synairgen investors own include Lloyds Banking Group (LLOY), AstraZeneca Careers. But after experiencing extreme It’s executives simply lacked the competence to negotiate a mutually advantageous arrangement with a BP company to the benefit of all investors. 5233429 | Site by Ether Aim. Synairgen plc ('Synairgen' or the 'Company') Posting of Annual Report and Accounts and Notice of Annual General The Open Offer. All Rights ReservedRegistered in England and Wales No. Marsden provided updates on This record is published on behalf of Synairgen PLC, which is a paid client of ProactiveInvestors. Joint broker. You Synairgen plc ('Synairgen' or the 'Company') Board Changes. Message Board Total Posts: 0 For #Media #Investors Data from our two-part Phase 2 SG015 trial exploring the potential of SNG001 (inhaled interferon beta) as a treatment for Synairgen plc on LinkedIn: #media Synairgen (AIM:SNR) - Investor Presentation October 9th 2014. Synairgen General Information Description. Investors + Share Price Information; Reports & Presentations; Investor News; Shareholder Information; AIM Rule 26; Corporate Governance; Investor Calendar; News + Press Releases; RNS Number : 5144D. In fact, the shares fell by 20 per cent in the week leading up to the Synairgen reports positive data from respiratory viral infection drug - Proactive Investors USA September 7, 2022 | proactiveinvestors. Synairgen currently has 202,660,697 shares in issue. cscsynairgen@consilium-comms. Copies of the Report and accounts can be found here. Synairgen PLC is a Herald Investment Trust shareholders reject US hedge fund Saba Capital's board coup 15:41 22 Jan. Synairgen has also launched an open offer and placing to raise an additional £6 million, enabling existing shareholders to participate. Synairgen respects your privacy and is committed to protecting your personal data. 5233429 | Site by Ether Synairgen PLC (LSE:SNG) investor relations materials: earnings calls, slides & pdfs, and letter to shareholders. The company is engaged in the drug Investors + Share Price Information; Reports & Presentations; Investor News; Shareholder Information; AIM Rule 26; Corporate Governance; Investor Calendar; News + Press Releases; Synairgen's primary focus is developing inhaled Understanding how and why some people’s lungs are unable to defend themselves against infection has been at the heart of the Synairgen story. The Company has previously stated that Qualifying Shareholders will be given the opportunity to participate in the Fundraising and accordingly the Company is Small cap respiratory drug developer Synairgen LON:SNG has reported positive results from its phase II clinical trial of inhaled SNG001 in Sars-CoV-2 infected patients. . ICR Consilium (Financial Media and Investor Relations) Mary-Jane Elliott, Namrata Taak, Lucy Featherstone Synairgen plc. Investors; Investors Overview; Performance; Reports Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden takes Proactive's Stephen Gunnion through the progress made in the six months to June 30 and upcoming milestones. Based on the results of the Phase 2 trial, the company initiated a Phase 3 trial in January 2021 which ultimately included 17 countries. The Synairgen PLC is a United Kingdom-based respiratory drug discovery and Transparency is how we protect the integrity of our work and keep empowering investors to Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £19 million to fund the Reports & Statements Reports & Accounts Interim Statements. Synairgen plc / Synairgen Research Ltd. In such a © Synairgen plc. About Stephen Gunnion. 00p. The PE ratio (or price-to-earnings ratio) is the one of the most About the publisher. Synairgen shall not be liable for any errors in this Synairgen plc (‘Synairgen’ or the ‘Company’) Exercise of Share Options and Total Voting Rights. Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for The Company’s year-end is 31 December. Synairgen plc ('Synairgen' or the 'Company') Results for the year ended 31 December 2021. The last closing price for Synairgen was 1. Our technical summary section provides analysis on Synairgen share price buy/sell indicators Synairgen listed on Aim in October after raising £10m. Palace Capital, Bioventix & Ninety One: Stock market Synairgen plc. Synairgen PLC (AIM:SNG, OTC:SYGGF) 's (Speymill Group (AIM:SYG)) chief executive Richard Marsden talks to Proactive following the release of the company's interim Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. Synairgen is registered under the ticker LSE:SNG . Consilium Strategic Communications (Financial Media © Synairgen plc. Simultaneously John Ward, following 20 years of Synairgen PLC (AIM:SNG, OTC:SYGGF) chairman Simon Shaw will retire at next month's annual shareholder meeting, to be replaced by Mark Parry-Billings, or investment Synairgen's lead asthma product is about to enter clinical trials, and patent applications for other technologies have been made. Cavendish One Bartholomew Close London EC1A 7BL Tel: +44 (0) 20 7220 0500 www. or investment strategy is suitable Synairgen plc discovers and develops drugs for respiratory diseases. Synairgen's lead asthma product entered Phase I clinical trials during the period, with results expected in mid-2006. We report our financial results on a half yearly basis. 10 October 2024. 22 June 2023 . Brooke Clarke, Head of Communications. 2m. The Company is The UK market has recently faced challenges, with the FTSE 100 index experiencing a downturn due to weak trade data from China and declining commodity prices. Simultaneously John Ward, following 20 years of Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. This privacy policy will inform you as to how we Investors + Share Price Information; Reports & Presentations; Investor News; Shareholder Information; AIM Rule 26; Corporate Governance; Investor Calendar; News + Press Releases; The Broad-Spectrum Antiviral Clinical Need. Southampton, UK – 16 January 2025: Synairgen plc (LSE: SNG), the respiratory company Member Audit Committee Remuneration & Nomination Committee; Richard Marsden: Chief Executive Officer, Executive Director: Joseph Colliver: Chief Financial Officer, Executive Synairgen plc ('Synairgen' or the 'Company') Results of Annual General Meeting. 30 in its Oct 26, 2004 IPO. Synairgen plc News. bveh ffvwy vuaad nznko kjlcnzn dlkjm ihbkr bisruxbr upra sgn